New drug cocktail shows promise for Tough-to-Treat colon cancer

NCT ID NCT05854498

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing whether a combination of three drugs—liposomal irinotecan, TAS102, and bevacizumab—can help people with metastatic colorectal cancer that has not responded to prior treatments. About 50 adults with mismatch repair proficient tumors will receive the drugs in cycles. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal irinotecan, TAS102, and bevacizumab
What this could lead to: If successful, this combination could offer a new treatment option for patients with metastatic colorectal cancer who have not responded to standard therapies.
What could go wrong: This is a small, early-phase trial with only 50 participants, so results may not apply broadly. The combination may cause serious side effects, and it is not yet known if it improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of Wisconsin Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 52792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.